Mar 07, 2023 / 03:30PM GMT
Unidentified Analyst
Thanks, everybody, for joining the Autoimmune/Complement/Inflammation panel. With us today, we have three companies: we have Alpine Immune Sciences, we have Mitch Gold or the CEO of Alpine; we have Noreen Henig from Kezar Life Sciences; and we have Jonathan Zalevsky from Nektar Therapeutics. Thanks for our panelists for joining.
Questions and Answers:
Unidentified AnalystWe're going to start our discussion with some thematic questions, and then we're going to dive into a company-specific question. So in thematic questions, according to our consultants and experts in the field, some drug failures, certainly in autoimmune conditions may not be primarily due to efficacy, but also due to complex scoring system and complex endpoints being used. What steps have you taken to get past some of these challenges? And how do you think the FDA is going to respond to some of these potential changes in endpoints?
I guess, why don't we just start out with Mitch, and we're going to go progressively disorder.
Mitch Gold - Alpine
Trustpilot
